Full-Time

Clinical Data Manager I

Updated on 9/3/2026

Perceptive

Perceptive

1,001-5,000 employees

Imaging core labs and eClinical solutions

Compensation Overview

$52.5k - $75k/yr

Remote in USA

Remote

Remote within the United States; candidates preferred from AZ, CT, DE, FL, GA, IL, MA, MO, NH, NJ, NC, PA, UT, VA.

Category
Biology & Biotech (1)

Get referred to Perceptive

See people who can refer or advise you

Responsibilities
  • Attending and participating in sponsor meetings
  • Managing all data management deliverables for assigned studies
  • Understanding the requirements for study implementation and data collection
  • Collaborating with project team to develop study-specific edit check criteria
  • Defining, running, and reviewing edit checks and resolving discrepant data
  • Maintaining organized, complete, and up-to-date study documentation
  • Performing study setup, specifications, and obtaining approvals as needed
  • Coordinating and documenting the receipt and processing of electronic or ancillary data received from outside sources (e.g., data received from other central laboratories, CROs, or Sponsors)
  • Keeping supervisor informed of project status
  • Reviewing data and identifying errors/inconsistencies
  • Collaborating with appropriate project team to resolve data issues
  • Tracking outstanding issues and following-up until resolution
  • Ensuring accuracy in manipulation and scrutiny of clinical data and that CDM activities are carried out according to regulatory guidelines
  • Other duties as assigned
Desired Qualifications
  • Remote role; candidates located in AZ, CT, DE, FL, GA, IL, MA, MO, NH, NJ, NC, PA, UT, VA preferred

Generate a clear, concise company summary for Perceptive based on the provided description.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$15M

Headquarters

New Haven, Connecticut

Founded

2000

Get referred to Perceptive

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Perceptive Discovery launched α-Sight in April 2026 with MH3D, targeting oncology radioligands.
  • January 2026 brought $15 million for At-211 infrastructure across U.S. and U.K. sites.
  • April 2026 Trialzen and Kayentis alliances broaden Perceptive eClinical's commercialization and integration reach.

What critics are saying

  • Palantir's 2026 lawsuit against Percepta AI highlights talent-poaching and confidentiality vulnerability.
  • WCG and other imaging consolidators keep compressing Perceptive's core-lab pricing power.
  • If Perceptive misses alpha-imaging execution, CapVest's 2026 investment stops scaling returns.

What makes Perceptive unique

  • Perceptive spans discovery, imaging, and RTSM across one R&D workflow.
  • Its 2026 α-Sight partnership adds rare alpha-radiopharmaceutical imaging for Actinium-225 and Astatine-211.
  • Perceptive's 50-year lineage and 400-plus approvals signal embedded regulatory credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Remote Work Options

Health Savings Account/Flexible Spending Account

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Adoption Assistance

Paid Holidays

Parental Leave

Education allowance

Tuition Reimbursement

Meal Benefits

Cycle to work scheme

Season ticket loan

Cycle to work scheme

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Apr 15th, 2026
Perceptive Discovery partners with MH3D to launch α-Sight™ for alpha radiopharmaceutical imaging

Perceptive Discovery has partnered with MH3D to launch α-Sight™, a preclinical imaging service for visualising alpha-emitting radiopharmaceuticals. The offering addresses imaging limitations in alpha-emitting therapies, which are increasingly used in oncology, by providing high-sensitivity, quantitative whole-body imaging. α-Sight™ combines MH3D's Alpha-SPECT™ Mini platform with Perceptive Discovery's expertise in preclinical imaging and radiochemistry. The service supports multi-isotope imaging for therapies using Actinium-225 and Astatine-211, integrated with VivoQuant™ for advanced analysis. Perceptive Discovery will serve as MH3D's exclusive service provider whilst collaborating on product enhancements. The platform supports biodistribution studies, tumour targeting validation and pharmacokinetic assessment to accelerate radioligand therapy development.

PR Newswire
Jan 8th, 2026
Perceptive Discovery secures $15M to expand radiochemistry and cell assay capabilities

Perceptive Discovery, the preclinical services division of Perceptive, has announced $15 million in strategic investments from shareholder CapVest Partners to expand its radiochemistry, cell assay and in vitro biology capabilities. The funding will support development services for oncology and radiopharmaceutical programmes from discovery through early clinical translation. The investment will significantly expand Perceptive Discovery's Astatine-211 infrastructure globally across two sites in the US and UK. The new facilities will feature specialised research environments and dedicated scientific personnel to support At-211 labelling, method development and preclinical applications. The investment underscores CapVest's confidence in Perceptive Discovery's business potential and reinforces the company's commitment to delivering integrated, high-quality preclinical workflows for drug development programmes.